Sector News

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

July 7, 2024
Life sciences

Wolfgang Wienand joins Lonza Group today as Chief Executive Officer (CEO). Wolfgang succeeds Albert M. Baehny, who took on the role of CEO ad interim in October 2023 and was Chairman of the Board of Directors of Lonza from 2018 to May 2024. Albert will work with Wolfgang to ensure a smooth leadership handover before he retires from Lonza this summer.

Jean-Marc Huët, Chairman of the Board of Directors, Lonza, commented: “On behalf of the Board, I extend a warm welcome to Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of CDMO experience, combined with deep strategic and scientific expertise. As Wolfgang joins, we look forward to an era of stable and structured growth under his leadership.”

Wolfgang Wienand, Chief Executive Officer, Lonza, commented: “Having worked in the CDMO industry for almost two decades, I always had great respect for Lonza’s ability to transform and grow at pace. It is a privilege to join this remarkable company as CEO. As I commence my journey with Lonza, we are embarking on a quest to meet and exceed the needs of our customers and their patients. I am greatly looking forward to working with the team to build on our strong foundations and create a strategy for us to deliver continued growth and reach our full potential.”

Since 2019, Wolfgang has held the role of CEO at Swiss CDMO, Siegfried. Wolfgang previously served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Prior to joining Siegfried in 2010, Wolfgang held a series of positions with increasing seniority at the German specialty chemicals company Evonik Industries.

Source: lonza.com

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach